-
Something wrong with this record ?
Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds
V. Palušová, T. Renzová, A. Verlande, T. Vaclová, M. Medková, L. Cetlová, M. Sedláčková, H. Hříbková, I. Slaninová, M. Krutá, V. Rotrekl, H. Uhlířová, A. Křížová, R. Chmelík, P. Veselý, M. Krafčíková, L. Trantírek, KO. Schink, S. Uldrijan,
Language English Country Switzerland
Document type Journal Article
Grant support
CZ.02.1.01/0.0/0.0/16_019/0000868
European Regional Development Fund
MUNI/A/1087/2018
Masarykova Univerzita
18-01396S
Grantová Agentura České Republiky
NV19-08-00450
Ministerstvo Zdravotnictví Ceské Republiky
CIISB - LM2018127
Ministerstvo Školství, Mládeže a Tělovýchovy
LM2015062
Ministerstvo Školství, Mládeže a Tělovýchovy
NLK
Free Medical Journals
from 2009
PubMed Central
from 2009
Europe PubMed Central
from 2009
ProQuest Central
from 2009-01-01
Open Access Digital Library
from 2009-01-01
Open Access Digital Library
from 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2009
- Publication type
- Journal Article MeSH
BRAF inhibitors can delay the progression of metastatic melanoma, but resistance usually emerges, leading to relapse. Drugs simultaneously targeting two or more pathways essential for cancer growth could slow or prevent the development of resistant clones. Here, we identified pyridinyl imidazole compounds SB202190, SB203580, and SB590885 as dual inhibitors of critical proliferative pathways in human melanoma cells bearing the V600E activating mutation of BRAF kinase. We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells. Pyridinyl imidazole compounds directly inhibit BRAF V600E kinase. Moreover, they interfere with the endolysosomal compartment, promoting the accumulation of large acidic vacuole-like vesicles and dynamic changes in mTOR signaling. A transient increase in mTORC1 activity is followed by the enrichment of the Ragulator complex protein p18/LAMTOR1 at contact sites of large vesicles and delocalization of mTOR from the lysosomes. The induced disruption of the endolysosomal pathway not only disrupts mTORC1 signaling, but also renders melanoma cells sensitive to endoplasmic reticulum (ER) stress. Our findings identify new activities of pharmacologically relevant small molecule compounds and provide a biological rationale for the development of anti-melanoma therapeutics based on the pyridinyl imidazole core.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20019055
- 003
- CZ-PrNML
- 005
- 20201123124541.0
- 007
- ta
- 008
- 201103s2020 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/cancers12061516 $2 doi
- 035 __
- $a (PubMed)32531927
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Palušová, Veronika $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 664/53, 656 91 Brno, Czech Republic.
- 245 10
- $a Dual Targeting of BRAF and mTOR Signaling in Melanoma Cells with Pyridinyl Imidazole Compounds / $c V. Palušová, T. Renzová, A. Verlande, T. Vaclová, M. Medková, L. Cetlová, M. Sedláčková, H. Hříbková, I. Slaninová, M. Krutá, V. Rotrekl, H. Uhlířová, A. Křížová, R. Chmelík, P. Veselý, M. Krafčíková, L. Trantírek, KO. Schink, S. Uldrijan,
- 520 9_
- $a BRAF inhibitors can delay the progression of metastatic melanoma, but resistance usually emerges, leading to relapse. Drugs simultaneously targeting two or more pathways essential for cancer growth could slow or prevent the development of resistant clones. Here, we identified pyridinyl imidazole compounds SB202190, SB203580, and SB590885 as dual inhibitors of critical proliferative pathways in human melanoma cells bearing the V600E activating mutation of BRAF kinase. We found that the drugs simultaneously disrupt the BRAF V600E-driven extracellular signal-regulated kinase (ERK) mitogen-activated protein kinase (MAPK) activity and the mechanistic target of rapamycin complex 1 (mTORC1) signaling in melanoma cells. Pyridinyl imidazole compounds directly inhibit BRAF V600E kinase. Moreover, they interfere with the endolysosomal compartment, promoting the accumulation of large acidic vacuole-like vesicles and dynamic changes in mTOR signaling. A transient increase in mTORC1 activity is followed by the enrichment of the Ragulator complex protein p18/LAMTOR1 at contact sites of large vesicles and delocalization of mTOR from the lysosomes. The induced disruption of the endolysosomal pathway not only disrupts mTORC1 signaling, but also renders melanoma cells sensitive to endoplasmic reticulum (ER) stress. Our findings identify new activities of pharmacologically relevant small molecule compounds and provide a biological rationale for the development of anti-melanoma therapeutics based on the pyridinyl imidazole core.
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Renzová, Tereza $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Verlande, Amandine $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Vaclová, Tereza $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Medková, Michaela $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Cetlová, Linda $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Sedláčková, Miroslava $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Hříbková, Hana $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Slaninová, Iva $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Krutá, Miriama $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Rotrekl, Vladimír $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 664/53, 656 91 Brno, Czech Republic.
- 700 1_
- $a Uhlířová, Hana $u Institute of Physical Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technická 2896/2, 616 69 Brno, Czech Republic. CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
- 700 1_
- $a Křížová, Aneta $u CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
- 700 1_
- $a Chmelík, Radim $u Institute of Physical Engineering, Faculty of Mechanical Engineering, Brno University of Technology, Technická 2896/2, 616 69 Brno, Czech Republic. CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
- 700 1_
- $a Veselý, Pavel $u CEITEC-Central European Institute of Technology, Brno University of Technology, Purkyňova 656/123, 612 00 Brno, Czech Republic.
- 700 1_
- $a Krafčíková, Michaela $u National Centre for Biomolecular Research, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Trantírek, Lukáš $u CEITEC-Central European Institute of Technology, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic.
- 700 1_
- $a Schink, Kay Oliver $u Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Montebello, N-0379 Oslo, Norway. Department of Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Montebello, N-0379 Oslo, Norway.
- 700 1_
- $a Uldrijan, Stjepan $u Faculty of Medicine, Masaryk University, Kamenice 753/5, 625 00 Brno, Czech Republic. International Clinical Research Center, St. Anne's University Hospital Brno, Pekařská 664/53, 656 91 Brno, Czech Republic.
- 773 0_
- $w MED00173178 $t Cancers $x 2072-6694 $g Roč. 12, č. 6 (2020)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32531927 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201103 $b ABA008
- 991 __
- $a 20201123124540 $b ABA008
- 999 __
- $a ind $b bmc $g 1585835 $s 1109253
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 12 $c 6 $e 20200610 $i 2072-6694 $m Cancers $n Cancers $x MED00173178
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000868 $p European Regional Development Fund
- GRA __
- $a MUNI/A/1087/2018 $p Masarykova Univerzita
- GRA __
- $a 18-01396S $p Grantová Agentura České Republiky
- GRA __
- $a NV19-08-00450 $p Ministerstvo Zdravotnictví Ceské Republiky
- GRA __
- $a CIISB - LM2018127 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- GRA __
- $a LM2015062 $p Ministerstvo Školství, Mládeže a Tělovýchovy
- LZP __
- $a Pubmed-20201103